Payment overview · 2025
General Payments
$267.31
16 reported records · 11 companies
Healthcare provider profile · identity verified
Summer Raye Tucker, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · CAMPBELLSVILLE, KY · NPI 1659505113
Verified facts
What the public records show
CMS Open Payments records show Summer Raye Tucker, D.O. received $267.31 in general payments during 2025 across 16 reported records.
ABBVIE INC. accounted for 18.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Rybelsus, Trintellix, Ubrelvy, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Ubrelvy by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VIBERZI as an associated drug or biological on 11354 records involving 5020 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Viberzi by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Vraylar by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Nuedexta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 151 claims for Eliquis by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $49.33 | 18.4% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $48.90 | 18.3% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $34.22 | 12.8% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $29.11 | 10.9% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $18.25 | 6.8% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $15.29 | 5.7% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.05 | 5.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.02 | 5.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.40 | 5.4% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $13.96 | 5.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.78 | 5.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $267.31 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $34.22 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $32.97 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $32.97 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $29.11 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $29.03 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $29.03 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $20.30 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $18.25 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.93 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $15.29 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.05 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.05 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.02 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $14.40 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $13.96 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $13.78 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 61 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 101 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 42 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VIBERZI open payments reported associated product |
CMS Open Payments — General Payments 11354 supporting records · 5020 recipient NPIs · example record 1201352948 |
Viberzi · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
20 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
61 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
101 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
17 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
151 | 15 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 524 | 76 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 398 | 74 |
| Omeprazole | Omeprazole | 316 | 64 |
| Pantoprazole Sodium | Pantoprazole Sodium | 313 | 51 |
| Famotidine | Famotidine | 309 | 57 |
| Gabapentin | Gabapentin | 309 | 50 |
| Amlodipine Besylate | Amlodipine Besylate | 306 | 57 |
| Montelukast Sodium | Montelukast Sodium | 290 | 46 |
| Lisinopril | Lisinopril | 252 | 57 |
| Metoprolol Succinate | Metoprolol Succinate | 246 | 51 |
| Metoprolol Tartrate | Metoprolol Tartrate | 236 | 40 |
| Atorvastatin Calcium | Atorvastatin Calcium | 224 | 41 |
| Escitalopram Oxalate | Escitalopram Oxalate | 218 | 31 |
| Tamsulosin Hcl | Tamsulosin Hcl | 212 | 37 |
| Metformin Hcl Er | Metformin Hcl | 200 | 40 |
| Fluticasone Propionate | Fluticasone Propionate | 187 | 51 |
| Losartan Potassium | Losartan Potassium | 181 | 33 |
| Furosemide | Furosemide | 174 | 35 |
| Potassium Chloride | Potassium Chloride | 164 | 27 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 160 | 27 |
| Quetiapine Fumarate | Quetiapine Fumarate | 159 | 16 |
| Liothyronine Sodium | Liothyronine Sodium | 154 | 22 |
| Eliquis | Apixaban | 151 | 15 |
| Pregabalin | Pregabalin | 151 | 21 |
| Simvastatin | Simvastatin | 147 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 146 | 27 |
| Sertraline Hcl | Sertraline Hcl | 146 | 25 |
| Valsartan | Valsartan | 141 | 30 |
| Carvedilol | Carvedilol | 132 | 26 |
| Tramadol Hcl | Tramadol Hcl | 130 | 30 |
| Sucralfate | Sucralfate | 126 | 28 |
| Fenofibrate | Fenofibrate | 124 | 18 |
| Donepezil Hcl | Donepezil Hcl | 122 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 121 | 23 |
| Lorazepam | Lorazepam | 118 | 30 |
| Diclofenac Sodium | Diclofenac Sodium | 111 | 29 |
| Trazodone Hcl | Trazodone Hcl | 111 | 23 |
| Finasteride | Finasteride | 110 | 17 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 102 | 26 |
| Metformin Hcl | Metformin Hcl | 102 | 23 |
| Estradiol | Estradiol | 101 | 29 |
| Ozempic | Semaglutide | 101 | 12 |
| Spironolactone | Spironolactone | 101 | 16 |
| Xarelto | Rivaroxaban | 96 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 91 | 25 |
| Mirtazapine | Mirtazapine | 89 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 88 | 34 |
| Alprazolam | Alprazolam | 87 | 14 |
| Methylprednisolone | Methylprednisolone | 83 | 60 |
| Levetiracetam | Levetiracetam | 82 | 13 |
| Bumetanide | Bumetanide | 81 | suppressed |
| Allopurinol | Allopurinol | 78 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 77 | 14 |
| Clonazepam | Clonazepam | 74 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 72 | 12 |
| Myrbetriq | Mirabegron | 71 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 71 | 15 |
| Buspirone Hcl | Buspirone Hcl | 70 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 70 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 70 | 14 |
| Atenolol | Atenolol | 66 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 66 | 11 |
| Baclofen | Baclofen | 65 | 14 |
| Mounjaro | Tirzepatide | 61 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 60 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 60 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 59 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 59 | 26 |
| Cefdinir | Cefdinir | 58 | 41 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 58 | suppressed |
| Azithromycin | Azithromycin | 56 | 47 |
| Meloxicam | Meloxicam | 56 | 13 |
| Olanzapine | Olanzapine | 55 | suppressed |
| Mupirocin | Mupirocin | 53 | 27 |
| Glipizide Er | Glipizide | 51 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 50 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 47 | 31 |
| Chlorthalidone | Chlorthalidone | 46 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 46 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 45 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 45 | suppressed |
| Bupropion Xl | Bupropion Hcl | 44 | suppressed |
| Aripiprazole | Aripiprazole | 43 | suppressed |
| Memantine Hcl | Memantine Hcl | 43 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 42 | 15 |
| Vraylar | Cariprazine Hcl | 42 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 41 | suppressed |
| Linzess | Linaclotide | 41 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 41 | suppressed |
| Celecoxib | Celecoxib | 40 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 40 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 39 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 37 | suppressed |
| Ezetimibe | Ezetimibe | 37 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 37 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 36 | suppressed |
| Nystatin | Nystatin | 35 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 33 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 33 | 26 |
| Paroxetine Hcl | Paroxetine Hcl | 33 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 32 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 31 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 31 | suppressed |
| Methocarbamol | Methocarbamol | 30 | 15 |
| Testosterone Cypionate | Testosterone Cypionate | 30 | suppressed |
| Belsomra | Suvorexant | 29 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 29 | suppressed |
| Fluconazole | Fluconazole | 28 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 27 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 27 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 26 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 26 | suppressed |
| Repatha Sureclick | Evolocumab | 25 | suppressed |
| Risperidone | Risperidone | 25 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 23 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 23 | suppressed |
| Primidone | Primidone | 23 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 22 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Topiramate | Topiramate | 22 | suppressed |
| Febuxostat | Febuxostat | 21 | suppressed |
| Lovastatin | Lovastatin | 21 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Prolia | Denosumab | 20 | 11 |
| Sotalol | Sotalol Hcl | 20 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 20 | suppressed |
| Klor-Con M20 | Potassium Chloride | 19 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 19 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 18 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 18 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 18 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 18 | suppressed |
| Viberzi | Eluxadoline | 18 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 17 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 12 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 17 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Metronidazole | Metronidazole | 16 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 16 | suppressed |
| Rybelsus | Semaglutide | 16 | suppressed |
| Ursodiol | Ursodiol | 16 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 15 | 15 |
| Diazepam | Diazepam | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Misoprostol | Misoprostol | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 11 |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 14 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Loperamide | Loperamide Hcl | 14 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Cephalexin | Cephalexin | 13 | suppressed |
| Dexilant | Dexlansoprazole | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Fluocinonide | Fluocinonide | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Nystop | Nystatin | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Trospium Chloride | Trospium Chloride | 13 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 13 | suppressed |
| Zafirlukast | Zafirlukast | 13 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Ubrelvy | Ubrogepant | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Dulera | Mometasone/Formoterol | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 11 | suppressed |
| Praluent Pen | Alirocumab | 11 | suppressed |
| Prednisone | Prednisone | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $267.31 · 16 records | ABBVIE INC. | Auvelity, BREZTRI, EVENITY, FANAPT, JARDIANCE, MOUNJARO, NURTEC ODT, Ozempic, QULIPTA, REXULTI, Rybelsus, TRINTELLIX, UBRELVY, VRAYLAR, Wegovy, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error